En Español | Plain Text Version | Skip Navigation
Search this site:

Target Nomination: Monoclonal Antibody Production

Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Awards
Contracts Management
Review Committees
Funding News

Program Areas

Training & Career Awards

Research Programs

Find People

About NINDS

Email this page

Print-friendly version

Download Adobe Reader

Purpose: As a result of a partnership between the Office of Rare Diseases (ORD) and the National Institute of Neurological Disorders and Stroke, we are requesting target nominations for the production of monoclonal antibodies that would be useful for basic and clinical research of rare diseases. Targets involved in all the rare diseases are eligible for consideration.

Name of nominator:
Email address:
Affiliation:
Gene Name: (example: Fibroblast growth factor 14 (fgf14))
Identifying information for target/antigen. (Genpept accession number) (example: NP_071559)
Brief description of the proposed target/antigen (full length protein, specific region or peptide sequence). (example: The target is Fibroblast Growth Factor 14. A fusion protein consisting of amino acids 1-252 (full-length) of mouse FGF14b will be provided.)
Indicate the species origin of the antigen/target [Our primary focus is on human antigens, however target nominations that would allow the generation of antibodies that cross-react with both human and other mammalian species could be of great utility especially for functional analyses.] (example: The target is the mouse protein. However, there is 98% identity with the human sequence.)
Briefly describe the biological importance of the target protein/antigen. (example: Humans with an autosomal dominant missense mutation in fibroblast growth factor 14 (FGF14) have impaired cognitive abilities and slowly progressive spinocerebellar ataxia.)
Briefly describe the importance of the proposed antibodies to the rare disease research community. (example: Information about the importance of the Ab to the wider research community should be put here).
Briefly describe the availability and suitability (or lack thereof) of existing polyclonal and/or monoclonal antibodies. (example: None of the existing antibodies (polyclonal) recognize FGF14 specifically.)
Please indicate any reagents (fusion proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) you could provide to a monoclonal antibody production facility to aid in the development and characterization of these antibodies. (example: I can provide a full length fusion protein of the b splice variant, tagged cDNAs for screening in COS cells and samples from knockout mice.)
If fusion proteins cannot be supplied, please indicate if you can provide advice on peptides to be synthesized. Costs for purchasing synthetic peptides would be born by ORD and NINDS. (example: A fusion protein is being provided.)
Please indicate your willingness to screen a limited number of hybridoma clones (less than 20) to identify those clones which produce useful monoclonal antibody. (example: I am willing and able to screen a limited number of clones.. In the actual example, the resulting mouse monoclonal antibody was of the IgG1 isotype, recognized the a and b splice variants of FGF14 from mouse, human and rat, and did not cross-react with FGF11, 12 or 13.)

Responses to any individual elements of the RFI are optional. The NIH site will permit anonymous responses. Responders should be aware that the information provided will be analyzed and may appear in various reports. Additionally, the government cannot guarantee the confidentiality of the information provided.

Specific questions about this RFI should be directed to the contact listed below:

Randall R. Stewart, Ph.D.
Program Director for Channels, Synapses and Circuits
National Institute of Neurological Disorders & Stroke
National Institutes of Health
6001 Executive Blvd., Room 2135
Bethesda, MD 20892-9523
Phone: 301-496-1917
Fax: 301-402-1501
E-mail: stewartr@ninds.nih.gov

Last updated December 15, 2008